Mesenchymal Stromal Cell Therapy Alleviates Ovalbumin-Induced Chronic Airway Remodeling by Suppressing M2 Macrophage Polarization
- PMID: 38316671
- DOI: 10.1007/s10753-024-01977-9
Mesenchymal Stromal Cell Therapy Alleviates Ovalbumin-Induced Chronic Airway Remodeling by Suppressing M2 Macrophage Polarization
Abstract
Chronic asthma is characterized by airway hyperresponsiveness, inflammation, and remodeling. Previous studies have shown that mesenchymal stromal/stem cells (MSCs) exert anti-inflammatory effects on asthma via regulation of the immune cells. However, the therapeutic mechanism of MSCs, especially the mechanism of airway remodeling in chronic asthma, remains to be elucidated. Here, we aimed to investigate the therapeutic effect of MSCs on airway remodeling in chronic asthma and explored the mechanisms by analyzing the polarization phenotype of macrophages in the lungs. We established a mouse model of chronic asthma induced by ovalbumin (OVA) and evaluated the effect of MSCs on airway remodeling. The data showed that MSCs treatment before the challenge exerted protective effects on OVA-induced chronic asthma, i.e., decreased the inflammatory cell infiltration, Th2 cytokine levels, subepithelial extracellular matrix deposition, and transforming growth factor β (TGF-β)/Smad signaling. Additionally, we found that MSCs treatment markedly suppressed macrophage M2 polarization in lung tissue. At the same time, MSCs treatment inhibited NF-κB p65 nuclear translocation, ER stress, and oxidative stress in the OVA-induced chronic allergic airway remodeling mice model. In conclusion, these results demonstrated that MSCs treatment prevents OVA-induced chronic airway remodeling by suppressing macrophage M2 polarization, which may be associated with the dual inhibition of ER stress and oxidative stress. This discovery may provide a new theoretical basis for the future clinical application of MSCs.
Keywords: ER stress; airway remodeling; asthma.; macrophage polarization; mesenchymal stromal/stem cells; oxidative stress.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Suppressive effect of compact bone-derived mesenchymal stem cells on chronic airway remodeling in murine model of asthma.Int Immunopharmacol. 2014 May;20(1):101-9. doi: 10.1016/j.intimp.2014.02.028. Epub 2014 Mar 6. Int Immunopharmacol. 2014. PMID: 24613203
-
Eicosapentaenoic Acid Enhances the Effects of Mesenchymal Stromal Cell Therapy in Experimental Allergic Asthma.Front Immunol. 2018 May 24;9:1147. doi: 10.3389/fimmu.2018.01147. eCollection 2018. Front Immunol. 2018. PMID: 29881388 Free PMC article.
-
Bone Marrow, Adipose, and Lung Tissue-Derived Murine Mesenchymal Stromal Cells Release Different Mediators and Differentially Affect Airway and Lung Parenchyma in Experimental Asthma.Stem Cells Transl Med. 2017 Jun;6(6):1557-1567. doi: 10.1002/sctm.16-0398. Epub 2017 Apr 20. Stem Cells Transl Med. 2017. PMID: 28425576 Free PMC article.
-
Molecular Pathways Underlying the Therapeutic Effect of Stem Cells during Asthmatic Changes.Iran J Allergy Asthma Immunol. 2024 Dec 29;23(6):600-624. doi: 10.18502/ijaai.v23i6.17372. Iran J Allergy Asthma Immunol. 2024. PMID: 39985489 Review.
-
New mesenchymal stem/stromal cell-based strategies for osteoarthritis treatment: targeting macrophage-mediated inflammation to restore joint homeostasis.J Mol Med (Berl). 2025 Jun;103(6):651-669. doi: 10.1007/s00109-025-02547-8. Epub 2025 Apr 24. J Mol Med (Berl). 2025. PMID: 40272537 Review.
References
-
- Mims, J.W. 2015. Asthma: Definitions and pathophysiology. International Forum of Allergy & Rhinology 5 (Suppl 1): S2–S6. https://doi.org/10.1002/alr.21609 . - DOI
-
- Saradna, A., D.C. Do, S. Kumar, Q.L. Fu, and P. Gao. 2018. Macrophage polarization and allergic asthma. Translational Research 191: 1–14. https://doi.org/10.1016/j.trsl.2017.09.002 . - DOI - PubMed
-
- Mattoo, H., D. Bangari, S. Cummings, Z. Humulock, D. Habiel, E. Xu, N. Pate, R. Resnick, V. Savova, G. Qian, C. Beil, E. Rao, F. Nestle, P. Bryce, and A. Subramaniam. 2023. Molecular features and stages of pulmonary fibrosis driven by type 2 inflammation. American Journal of Respiratory Cell and Molecular Biology 69: 404–421. https://doi.org/10.1165/rcmb.2022-0301OC . - DOI - PubMed
-
- Hong, S., Y. Lu, S. Chen, C. Hsu, Y. Lu, C. Wang, and K. Huang. 2023. Targeting pathogenic macrophages by the application of SHP-1 agonists reduces inflammation and alleviates pulmonary fibrosis. Cell Death & Disease 14: 352. https://doi.org/10.1038/s41419-023-05876-z . - DOI
-
- Lee, H., J. Hur, J. Kang, C. Rhee, and S. Lee. 2021. MicroRNA-21 inhibition suppresses alveolar M2 macrophages in an ovalbumin-induced allergic asthma mice model. Allergy, Asthma & Immunology Research 13: 312–329. https://doi.org/10.4168/aair.2021.13.2.312 . - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical